The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Determining the progression of SMM using predictive biomarkers
Could the progression of smoldering multiple myeloma (SMM) be better predicted? In this interview, Irene Ghobrial, MD, from the Dana-Farber Cancer Institute, Boston, MA, offers her expertise on this topic; explaining that there are genomic alterations, such as translocations or amplifications, that can better predict which patients will progress to high-risk SMM. With this development, the hope is to identify and treat those who will progress much earlier. Dr Ghobrial also discusses the importance of the MAP kinase signaling pathway and KRAS mutations in predicting progression. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
